Pharmacoeconomic Evaluation and Clinical Outcomes of Channa as an Adjuvant to 20% Human Albumin Therapy in Patients with Chronic Kidney Disease: A Cost-Effectiveness Analysis (CEA) at Imelda Pekerja Indonesia General Hospital
Keywords:
Channa striata, chronic kidney disease, cost-effectiveness analysis, pharmacoeconomics, hypoalbuminemia, human albuminAbstract
Hypoalbuminemia is a common complication in patients with Chronic Kidney Disease (CKD) and is associated with increased morbidity, mortality, and length of hospital stay. Human albumin therapy is effective but costly; therefore, pharmacoeconomic evaluation of alternative therapies based on snakehead fish (*Channa striata*) extract is warranted. This study aimed to evaluate the cost-effectiveness and clinical outcomes of Channa as an adjuvant to 20% Human Albumin therapy in CKD patients with hypoalbuminemia at Imelda Pekerja Indonesia General Hospital, Medan. A descriptive observational study with retrospective data collection was conducted involving 35 patients who were divided into three treatment groups: Channa product, 20% Human Albumin, and a combination of both therapies. Effectiveness was assessed based on the increase in serum albumin levels (Δ albumin, g/dL), while costs were calculated based on direct costs of albumin therapy. Cost-effectiveness analysis was performed by calculating the Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER). The results showed that the total direct cost of albumin therapy was IDR 57,970,200, with the lowest cost observed in the Channa product group. The Channa product group had the lowest ACER (IDR 990,889 per g/dL), and the ICER analysis indicated that Channa was a dominant strategy, being both less costly and more effective. It was concluded that Channa therapy was the most cost-effective option for correcting hypoalbuminemia in CKD patients, while 20% Human Albumin remained important for severe conditions requiring rapid correction.
References
Purwoko, A., Setiawan, B., & Wahyuni, S. (2023). Hipoalbuminemia: Patofisiologi dan tatalaksana pada pasien rawat inap. Jurnal Penyakit Dalam Indonesia, 10(2), 88–97.
Witha, R., Aldi, Y., & Almahdy, A. (2024). Analisis efektivitas terapi human albumin 20% dibandingkan human albumin 25% pada pasien pascaoperasi bedah digestif dengan hipoalbuminemia. Jurnal Farmasi Klinik Indonesia, 13(1), 25–34.
Nababan, M. (2017). Prevalensi penyakit ginjal kronis di Indonesia berdasarkan survei Perhimpunan Nefrologi Indonesia. Jurnal Kesehatan Masyarakat Nasional, 12(3), 145–152.
Hasan, M., Pradana, R., & Yuliana, D. (2024). Kajian efektivitas biaya pemberian human albumin sebagai terapi tambahan pada pasien sirosis di Indonesia. Indonesian Journal of Clinical Pharmacy, 13(2), 110–120.
Arisanti, P. A. M., & Noviyani, R. (2025). Tinjauan sistematis efektivitas kapsul ikan gabus (Channa striata) terhadap peningkatan kadar albumin pada pasien hipoalbuminemia. Jurnal Farmasi Klinik Indonesia, 14(1), 1–12.
Andrajati, R., Supardi, S., & Sari, I. P. (2020). Farmakoekonomi: Konsep dan aplikasi dalam pelayanan kesehatan. Jakarta: Penerbit Buku Kedokteran EGC.
Kementerian Kesehatan Republik Indonesia. (2026). Pedoman kajian farmakoekonomi dalam pelayanan kesehatan. Jakarta: Kementerian Kesehatan RI.
Kidney Disease: Improving Global Outcomes (KDIGO). (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314.
Fitriansyah, A., Rahmawati, F., & Andayani, T. M. (2021). Mekanisme peningkatan sintesis albumin oleh ekstrak ikan gabus (Channa striata). Jurnal Sains Farmasi & Klinis, 8(2), 134–142.
Wahyuningtiyas, D. (2020). Analisis efektivitas dan biaya terapi albumin ekstrak ikan gabus murni dibandingkan human albumin 20% pada pasien hipoalbuminemia di RSUD Dr. Moewardi (Skripsi). Universitas Sebelas Maret, Surakarta.
Setiani, L. A., Hidayatullah, A., & Lestari, P. (2023). Cost-effectiveness analysis terapi albumin pada pasien rawat inap. Jurnal Farmasi Sains dan Komunitas, 20(1), 45–55.
Tomlinson, L. A., & Clase, C. M. (2019). Sex differences in the epidemiology and progression of chronic kidney disease. Nephrology Dialysis Transplantation, 34(7), 1098–1105.
Nugroho, S. A. (2016). Efektivitas ekstrak ikan gabus sebagai alternatif terapi albumin yang ekonomis. Jurnal Farmasi Indonesia, 8(1), 30–38.
Muryawan, M. H., Wijayahadi, N., & Mexitalia, M. (2019). Hubungan kadar albumin dengan lama rawat inap pada pasien anak. Jurnal Kedokteran Diponegoro, 8(1), 210–219.
Aprilia, N., Santoso, B., & Wulandari, R. (2024). Hipertensi sebagai faktor risiko utama penyakit ginjal kronis. Jurnal Kesehatan Masyarakat, 19(2), 99–108.
Heroweti, J., & Rokhmawati, D. (2023). Analisis efektivitas biaya (ACER dan ICER) terapi pada pasien rawat inap. Jurnal Ilmu Farmasi dan Farmasi Klinik, 20(2), 77–86.
